Nanosphere 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	NSPH
Entity Registrant Name	NANOSPHERE INC
Entity Central Index Key	1,105,184
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		8,233,652

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 12,339	$ 21,053
Restricted cash	4,000	0
Accounts receivable - net of allowance for doubtful accounts	3,314	4,292
Inventories	6,775	9,387
Other current assets	298	380
Total current assets	26,726	35,112
Property and equipment - net of accumulated depreciation	8,413	5,072
Intangible Assets - net of accumulated amortization	1,905	2,080
Other Assets	75	75
Total assets	37,119	42,339
Current liabilities:
Accounts payable	2,383	1,827
Accrued compensation	1,592	943
Other current liabilities	3,234	3,173
Debt - net	15,474	9,716
Total current liabilities	22,683	15,659
Total liabilities	22,683	15,659
STOCKHOLDERS' EQUITY:
Common stock, $0.01 par value; 150,000,000 shares authorized; 8,233,652 shares and 5,866,318 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	82	59
Additional paid-in capital	461,185	448,527
Accumulated deficit	(446,831)	(421,906)
Total stockholders’ equity	14,436	26,680
Total liabilities and stockholders' equity	37,119	42,339
Series A
STOCKHOLDERS' EQUITY:
Convertible preferred stock	0	0
Series B Preferred Stock
STOCKHOLDERS' EQUITY:
Convertible preferred stock	$ 0	$ 0

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
common stock, par value (usd per share)	$ 0.01	$ 0.01
common stock, shares authorized (shares)	150,000,000	150,000,000
common stock, shares issued (shares)	8,233,652	5,866,318
common stock, shares outstanding (shares)	8,233,652	5,866,318
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
preferred stock, shares authorized (shares)	10,000,000	10,000,000
Series A
preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Series B Preferred Stock
preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Product sales	$ 4,888	$ 3,688	$ 14,224	$ 9,643
Total revenue	4,888	3,688	14,224	9,643
Costs and expenses:
Cost of sales	3,931	2,361	8,801	6,053
Research and development	3,467	5,534	11,576	14,705
Sales, general, and administrative	5,409	5,054	16,240	17,436
Restructuring costs	0	0	513	0
Total costs and expenses	12,807	12,949	37,130	38,194
Loss from operations	(7,919)	(9,261)	(22,906)	(28,551)
Other income (expense):
Interest expense	(880)	(341)	(2,022)	(1,072)
Other income	1	0	3	5
Total other expense	(879)	(341)	(2,019)	(1,067)
Net, and comprehensive loss	(8,798)	(9,602)	(24,925)	(29,618)
Deemed dividend on convertible preferred stock, due to beneficial conversion feature	(1,133)	0	(6,936)	0
Loss attributable to common shareholders	$ (9,931)	$ (9,602)	$ (31,861)	$ (29,618)
Net loss per common share - basic and diluted	$ (1.31)	$ (2.52)	$ (4.81)	$ (7.77)
Weighted average number of common shares outstanding - basic and diluted	7,595	3,815	6,623	3,813

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
OPERATING ACTIVITIES:
Net loss	$ (24,925)	$ (29,618)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,269	1,306
Amortization of intangible assets	243	245
Amortization of financing costs and accretion of debt discount	436	241
Share-based compensation	740	2,631
Provision for doubtful accounts	102	89
Changes in operating assets and liabilities:
Accounts receivable	876	(572)
Inventories	(385)	(2,435)
Other current assets	82	(55)
Accounts payable	(104)	494
Accrued and other current liabilities	1,036	1,383
Net cash used in operating activities	(20,630)	(26,291)
INVESTING ACTIVITIES:
Purchases of property and equipment	(1,171)	(2,147)
Purchases of intangible asset	(68)
Restricted cash	(4,000)	0
Net cash used in investing activities	(5,239)	(2,147)
FINANCING ACTIVITIES:
Proceeds from the issuance of debt with warrants	20,000	0
Payments on debt	(9,916)	(1,175)
Debt issuance costs	(968)	0
Proceeds from the issuance of convertible preferred stock with warrants	8,800	0
Equity issuance costs	(761)	0
Proceeds from stock option exercise	0	653
Net cash provided by financing activities	17,155	(522)
Net decrease in cash and cash equivalents	(8,714)	(28,960)
Cash and cash equivalents - Beginning of period	21,053	41,467
Cash and cash equivalents - End of period	12,339	12,507
NONCASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of inventory to (from) property and equipment	2,780	747
Capital expenditures included in accounts payable	671	257
Conversion of convertible preferred stock to common stock	7,699	0
Deemed dividend on conversion of preferred stock to common stock	3,211	0
Deemed dividend on convertible preferred stock, due to beneficial conversion feature	3,725	0
Placement agent warrants in connection with convertible preferred stock	340	0
Warrants issued with convertible preferred stock	3,211	0
Warrants issued with debt	3,902	0
SUPPLEMENTAL DISCLOSURE:
Cash paid for interest	$ 1,266	$ 818

Condensed Statement of Stockhol

Condensed Statement of Stockholders Equity Statement - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Series B	Convertible Preferred StockSeries A	Convertible Preferred StockSeries B	Common Stock	Additional Paid in Capital	Accumulated Deficit
Balance beginning of period, shares at Dec. 31, 2014			0	0	5,866
Balance beginning of period at Dec. 31, 2014	$ 26,680		$ 0	$ 0	$ 59	$ 448,527	$ (421,906)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrants issued with debt	3,902					3,902
Issuance of convertible preferred stock, stock			4	4
Issuance of convertible preferred stock	8,800		$ 4,400	$ 4,400
Costs related to the issuance of convertible preferred stock	(761)		(388)	(373)
Issuance of placement agent warrants in connection with the convertible preferred stock	340		(175)	(165)		340
Issuance of warrants with convertible preferred stock	3,211		(1,606)	(1,605)		3,211
Beneficial conversion feature of convertible preferred stock			(2,227)	(1,498)		3,725
Deemed dividend related to immediate accretion of beneficial conversion feature of convertible preferred stock	(3,725)		2,227	1,498		(3,725)
Deemed dividend on conversion of preferred stock to common stock		$ (1,600)	$ 1,606	$ 1,605		(3,211)
Conversion of convertible preferred stock to common stock, shares			(4)	(4)	(2,372)
Conversion of convertible preferred stock to common stock			$ (3,837)	$ (3,862)	$ 23	7,676
Forfeiture of restricted stock, shares					(4)
Share-based compensation expense	740					740
Net loss	(24,925)						(24,925)
Balance end of period, shares at Sep. 30, 2015			0	0	8,234
Balance end of period at Sep. 30, 2015	$ 14,436		$ 0	$ 0	$ 82	$ 461,185	$ (446,831)

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Description of Business and Significant Accounting Policies	Description of Business and Significant Accounting Policies Nanosphere, Inc. (the “Company”) develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables simple, low cost, and highly sensitive genomic and protein testing on a single platform. Basis of Presentation - The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and in conformity with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, in the opinion of management, all adjustments, consisting only of normal recurring adjustments, unless otherwise noted herein, necessary to present fairly the results of operations, financial position and cash flows have been made. Therefore, these condensed financial statements should be read in conjunction with the Company’s most recent audited financial statements for the year ended December 31, 2014 and notes thereto included in the Company’s Annual Report on Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations expected for the full year. The accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Deferred Financing Costs - Costs incurred to issue debt are deferred and amortized as a component of interest expense using the effective interest method over the term of the related debt agreement. Amortization expense of deferred financing costs was $0.2 million and $0.3 million for the three and nine month periods ended September 30, 2015 , respectively, and $0.1 million for the three and nine month periods ended September 30, 2014, respectively. Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the condensed financial statements are related to inventories, property and equipment, intangible assets, debt, preferred stock, warrants, and share-based compensation. Actual results could differ from those estimates. Fair Value of Financial Instruments - The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable approximate their fair values. Fair value of debt was $15.6 million and $9.8 million at September 30, 2015 and December 31, 2014 , respectively. Reverse Stock Split - On April 7, 2015, the Company's Board of Directors and shareholders approved a 20 -to-1 reverse split of the Company's issued and outstanding common stock, effective at the close of business on April 8, 2015. The effect of this event has been reflected in all the share quantities and per share amounts in these financial statements. The shares of common stock authorized remained at 150 million and retained a par value of $0.01 . Debt, with Detachable Warrants - The Company accounts for debt with detachable warrants in accordance with ASC 470: Debt and allocated proceeds received to the debt and detachable warrants based on relative fair values. The Company assessed the classification of its common stock purchase warrants as of the date of the transaction and determined that such instruments meet the criteria for equity classification. The warrants are reported on the condensed balance sheet as a component of additional paid in capital within stockholders’ equity. The Company recorded the related issue costs and value ascribed to the warrants as a reduction of the debt. The discount is amortized utilizing the effective interest method over the term of the debt. The unamortized discount, if any, upon repayment of the notes will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the effective interest rate of the debt was 20.9% . The Company has also evaluated its debt and warrants in accordance with the provisions of ASC 815, Derivatives and Hedging , including consideration of embedded derivatives requiring bifurcation. Convertible Preferred Stock - The Company accounts for convertible preferred stock with detachable warrants in accordance with ASC 470: Debt and allocated proceeds received to the convertible preferred stock and detachable warrants based on relative fair values. The Company evaluated the classification of its convertible preferred stock and warrants and determined that such instruments meet the criteria for equity classification. The Company recorded the related issue costs and value ascribed to the warrants as a reduction of the convertible preferred stock. The Company has also evaluated its convertible preferred stock and warrants in accordance with the provisions of ASC 815, Derivatives and Hedging , including consideration of embedded derivatives requiring bifurcation. Beneficial conversion feature - The issuance of the convertible preferred stock generated a beneficial conversion feature (“BCF”), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective strike price that is less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the convertible preferred stock may be converted immediately, we have recognized the BCF as a deemed dividend in the statement of operations. Impairment of Intangible Assets - The Company monitors the carrying value of long-lived assets for potential impairment and tests the recoverability of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. Evaluation Equipment - The Company monitors inventory held at customer sites for evaluation (“Evaluation Equipment”). Upon determination that such Evaluation Equipment is no longer available for sale and is to remain with the customer, Evaluation Equipment is reclassified to property plant and equipment as leased equipment, which is typically after twelve months following initial placement. During the three and nine month periods ended September 30, 2015, the Company reclassified $2.9 million of Evaluation Equipment to property, plant, and equipment. The Company commences depreciation on the date of transfer and such Evaluation Equipment is depreciated over a three year period. New Accounting Pronouncements - In May 2014, the FASB issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers , (“ASU No. 2014-09”) an updated standard on revenue recognition. ASU No. 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU No. 2014-09, which will be effective for the Company in the first quarter of 2018 and may be applied on a full retrospective or modified retrospective approach. The Company is evaluating the impact of implementation and transition approach of this standard on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known (and reasonably knowable) at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company currently discloses its uncertainty about its ability to continue as a going concern. The Company does not expect the adoption of ASU No. 2014-15 to have a material impact on its disclosures or its consolidated financial statement. In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. ASU No. 2015-03 is effective for the interim and annual periods ending after December 15, 2015, with early adoption permitted. As of June 30, 2015, the Company adopted ASU No. 2015-03 and such adoption resulted in debt issuance costs for all periods presented to be reclassified to debt. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventories by replacing the lower of cost or market test with a lower of cost and net realizable value test. The guidance applies only to inventories for which cost is determined by methods other than last-in first-out ("LIFO") and the retail inventory method. The guidance in ASU No. 2015-11 is effective for periods beginning after December 15, 2016 and early adoption is permitted. The Company will adopt this pronouncement in the first quarter of 2017 and is currently evaluating the impact, if any, adoption will have on its financial position and results of operations. Reclassifications - Certain information as of December 31, 2014 presented in the financial statements have been reclassified to the current presentation. These reclassifications include: i) the reclassification of $0.1 million of debt issuance costs upon the early adoption of ASU No. 2015-03 to debt on the condensed balance sheets, ii) the combination of warrants to acquire common stock within additional paid in capital on the condensed balance sheets and condensed statement of stockholders’ equity, and iii) the separate presentation of depreciation and amortization and accounts receivable and provision for doubtful accounts on the condensed statements of cash flows, iv) the combination of foreign exchange gain/ loss and interest income on the income statement. These reclassifications had no impact on the results of operations, financial position, or cash flows. Restricted Cash - Any cash that is legally restricted from use is recorded in restricted cash on the condensed balance sheets. The new term loan facility (See Note 2) requires the Company to maintain a minimum account balance which is considered to be restricted cash. The restricted cash balance was $4 million on September 30, 2015 and there was no restricted cash on December 31, 2014. Comprehensive Loss - The Company’s comprehensive loss is equal to its net loss for all periods presented.

Liquidity and Capital Resources

Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2015
Liquidity and Capital Resources [Abstract]
Liquidity, Capital Resources and Recent Developments	Liquidity, Capital Resources and Recent Developments Liquidity and Capital Resources As of September 30, 2015 , the Company has incurred net losses of $446.8 million since inception, and has funded those losses primarily through the sale and issuance of equity securities and secondarily through the issuance of debt. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses in the foreseeable future. The Company had cash and cash equivalents of $16.3 million, of which $4 million is restricted cash as of September 30, 2015 and net cash used in operating activities of $20.6 million for the nine months period ended September 30, 2015 . In addition, our current term loan facility (“2015 Loan Agreement”) provides for minimum quarterly amortization ratios of (i) the aggregate of our cash operating expenses, cash interest expenses and capital expenditures, to (ii) our gross profits. The Company did not meet the required amortization ratio of 3.5 for the quarter ended September 30, 2015, and may not achieve the required amortization ratio of 2.6 for the quarter ending December 31, 2015. If the Company fails to satisfy the required amortization ratio for any two out of three successive quarters, the date on which the first amortization payment is due under the term loan facility would accelerate to the next following payment date, and the minimum quarterly amortization rate would increase to approximately $3.3 million, resulting in a payoff of the current amount outstanding under the term loan facility in six fiscal quarters. Management is uncertain that its current and anticipated cash resources will be sufficient to support currently forecasted operations through at least the next twelve months, and therefore, the Company will need additional debt or equity financing in the future to execute its business plan and to be able to continue as a going concern. Capital outlays and operating expenditures may increase over the next twelve months as the Company expands its infrastructure, manufacturing capacity and research and development activities to support commercialization of our products. These capital outlays and operating expenditures would be curtailed if the Company is not successful in raising additional funds. Many of the aspects of the Company’s forecasts involve management’s judgments and estimates that include factors that could be beyond our control and actual results could differ. These and other factors could cause our forecasted plans to be unsuccessful which could have a material adverse effect on our operating results, financial condition, and liquidity. Term Loan Facility with NSPH Funding LLC and SWK Funding LLC On May 14, 2015 (the "Closing Date") the Company entered into a Loan and Security Agreement ("2015 Loan Agreement") with NSPH Funding LLC, an affiliate of Life Sciences Alternative Funding, LLC, and SWK Funding LLC, as lenders (together, the “New Lenders”) providing for the New Lenders to advance term loans in an aggregate amount of up to $30 million (the “Loan”) to the Company. NSPH Funding LLC also agreed to act as agent under the loan facility (the “Collateral Agent”). Also on the Closing Date, concurrent with the Company's entry into the 2015 Loan Agreement, the Company drew down $20.0 million of the Loan, terminated its existing debt facility, and repaid approximately $8.9 million in full satisfaction of all outstanding liabilities and obligations under such prior debt facility. The remaining $10 million of the New Lenders’ commitment (the “Second Advance”) can be drawn upon satisfaction of certain other conditions on or before May 14, 2016, including the Company achieving trailing six month revenue of at least $12 million during any consecutive six month period; and the Company selling no less than 100 cumulative new units during any 12 month period starting January 1, 2015. There can be no assurance that the Company will achieve the foregoing requirements in order to be able to draw the Second Advance. Under the original terms of the 2015 Loan Agreement, the Company was required to (i) raise at least $6.0 million in net proceeds from either equity financings or licensing or strategic partnership transactions on or before January 14, 2016 (the “Capital Requirement”), and (ii) maintain a minimum of $3.0 million in accounts that are subject to a control agreement in favor of the Collateral Agent. As further described below, on June 11, 2015 the Company completed a registered direct offering of series B preferred stock and warrants to purchase shares of common stock for approximately $4.0 million in net proceeds to the Company. On July 29, 2015 the Company and the New Lenders entered into an amendment to the 2015 Loan Agreement (the “Amendment”) that reduced the Capital Requirement to $4.0 million and included the Lenders’ acknowledgement that the Capital Requirement has been fully satisfied. The Amendment also modified the minimum account balance in the Company’s accounts that are subject to a control agreement in favor of the Collateral Agent, by increasing the minimum balance to $4.0 million concurrent with the entry into the Amendment and providing that it shall increase to $5.0 million after the earlier of the funding of the Second Advance or December 31, 2016. Under the 2015 Loan Agreement, the Company will pay interest only (the “Interest Only Period”) on a quarterly basis until the earlier of (i) three years from the Closing Date or (ii) the Company’s failure to satisfy a ratio of certain expenses to gross profit as set forth in the 2015 Loan Agreement. At the conclusion of the Interest Only Period, the Company will be required to repay a portion of the outstanding principal and all accrued interest on a quarterly basis through the maturity date of the Loan depending on certain revenue thresholds established under the 2015 Loan Agreement, but subject to certain caps on the principal amount to be paid per fiscal quarter as established under the 2015 Loan Agreement. The term of the Loan (including the second tranche, if advanced) is six years , or earlier if the Company fails to satisfy a ratio of certain expenses to gross profits or if an event of default occurs, all as set forth in the 2015 Loan Agreement. Interest on the Loan will accrue at a rate of 11.50% per annum plus the greater of (i) 1.00% or (ii) LIBOR. The interest rate will increase by 5.00% upon the occurrence and during the continuation of an event of default under the 2015 Loan Agreement. A facility fee for the Loan of $0.45 million was paid upon execution of the 2015 Loan Agreement. A final fee equal to 5.00% of the aggregate principal amount of the Loan funded (without regard to prepayments during the term of the Loan) at such time will be due upon any repayment of the Loan or acceleration of the Loan. In the event that the Loan is prepaid or accelerated for any reason prior to the third anniversary of the Closing Date, a prepayment fee equal to 2.00% of the principal amount prepaid (if prior to the first anniversary of the Effective Date) or 1.00% (if after the first anniversary but prior to the third anniversary of the Closing Date) is also payable. The Loan is secured by substantially all of the assets of the Company, including, without limitation, the Company’s intellectual property. The 2015 Loan Agreement includes customary negative covenants that restrict the Company from incurring additional debt, paying dividends, disposing of material assets (except for sales in the ordinary course). The 2015 Loan Agreement also provides for customary events of default, including among others, nonpayment of principal, interest, fees or other amounts; material inaccuracy of representations; material adverse change; violation of covenants; and bankruptcy or insolvency of the Company. If an event of default occurs under the 2015 Loan Agreement, the entire outstanding balance would become immediately due and payable upon notice in certain instances from the Collateral Agent or New Lenders (or on an automatic basis in the event of a bankruptcy or insolvency event). As consideration for the funding of the Loan and the New Lenders’ commitment thereunder, on the Closing Date the Company issued warrants to the New Lenders to acquire an aggregate of up to 1,000,000 shares of common stock, par value $0.01 (the “Common Stock”) with an exercise price of $0.01 per share and an expiration date that is ten years from the date of the 2015 Loan Agreement (the “Lender Warrants”). At the time of issuance, the relative fair value of the warrants was estimated at $3.9 million using the Black-Scholes model and recorded as a debt discount. Series A Convertible Preferred Stock On May 11, 2015, the Company issued $4.4 million of series A convertible preferred stock (the "Series A Preferred Stock") (which are convertible into a total of 1,168,659 shares of common stock at a conversion price of $3.765 ) and warrants to purchase shares of common stock exercisable for up to 1,168,659 additional shares of common stock, in the aggregate at exercise price of $3.65 per share (the "Series A Investor Warrants"). In connection with the Series A Offering, and as partial payment of the placement agent’s fees in connection therewith, the Company issued to the placement agent and certain of its principals warrants to purchase an aggregate of 70,120 shares of common stock at an exercise price of $4.45 per share (the “Series A Placement Agent Warrants, and together with the Series A Investor Warrants, the “Series A Warrants”). The Series A Warrants are exercisable for 4.5 to 5 years commencing November 14, 2015. At the time of issuance, the relative fair value of the Series A Investor Warrants was estimated at $1.6 million using the Black-Scholes model and recorded as issuance costs. The Series A Preferred Stock is perpetual and does not have a required dividend right or voting rights and has a liquidation preference of $0.01 per share. As of September 30, 2015, all 4,400 shares of Series A Preferred Stock had been converted into 1,168,659 shares of common stock. The Company completed the issuance and sale of the Series A Preferred Stock and Series A Warrants on May 14, 2015. Net proceeds from the Series A Offering after placement agent fees and other offering expenses were approximately $4.0 million. Series B Convertible Preferred Stock On June 8, 2015, the Investors waived the Lock-Up Restriction and the Company issued $4.4 million of series B convertible preferred stock (the “Series B Preferred Stock”) (which are convertible into a total of 1,203,800 shares of common stock at a conversion price of $3.655 ) and warrants to purchase shares of common stock exercisable for up to 1,203,800 additional shares of common stock, in the aggregate at an exercise price of $3.54 per share (the “Series B Investor Warrants”). In connection with the Series B Offering, and as partial payment of the placement agent’s fees in connection therewith, the Company issued to the placement agent and certain of its principals warrants to purchase an aggregate of 72,230 shares of common stock at an exercise price of $3.54 per share (the “Series B Placement Agent Warrants, and together with the Series B Investor Warrants, the “Series B Warrants”). The Series B Warrants are exercisable for 4.5 to 5 years commencing December 11, 2015. At the time of issuance, the relative fair value of the Series B Investor Warrants was estimated at $1.6 million using the Black-Scholes model and recorded as issuance costs. The Series B Preferred Stock is perpetual and does not have a required dividend right or voting rights and has a liquidation preference of $0.01 per share. As of September 30, 2015, all 4,400 shares of Series B Preferred Stock has been converted into 1,203,800 shares of common stock. The Company completed the issuance and sale of the Series B Preferred Stock and Series B Warrants on June 11, 2015. Net proceeds from the Series B Offering after placement agent fees and other offering expenses were approximately $4.0 million. The Lender Warrants, Series A Warrants, and Series B Warrants can be settled in shares of our common stock by cashless exercise in lieu of payment of the exercise price at the option of the holder. The warrants contain no mandatory redemption features and no repurchase obligations requiring the transferring of assets and are for a fixed number of shares, except for customary anti-dilution adjustments. Under the original terms of the 2015 Loan Agreement, the Company was required to (i) raise at least $6.0 million in net proceeds from either equity financings or licensing or strategic partnership transactions on or before January 14, 2016 (the “Capital Requirement”), and (ii) maintain a minimum of $3.0 million in accounts that are subject to a control agreement in favor of the Collateral Agent. On June 11, 2015 the Company completed a registered direct offering of series B preferred stock and warrants to purchase shares of common stock for approximately $4.0 million in net proceeds to the Company. On July 29, 2015 the Company and the New Lenders entered into an amendment to the 2015 Loan Agreement (the “Amendment”) that reduced the Capital Requirement to $4.0 million and included the Lenders’ acknowledgement that the Capital Requirement has been fully satisfied. The Amendment also modified the minimum account balance in the Company’s accounts that are subject to a control agreement in favor of the Collateral Agent, by increasing the minimum balance to $4.0 million concurrent with the entry into the Amendment and providing that it shall increase to $5.0 million after the earlier of the funding of the Second Advance or December 31, 2016.

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes the Company's debt as of September 30, 2015 and December 31, 2014 : September 30, 2015 December 31, 2014 Silicon Valley Bank and Oxford Finance LLC $ — $ 9,919 Debt discount, inclusive of issue costs — (203 ) — 9,716 NSPH Funding LLC and SWK Funding LLC 20,000 — Debt discount, inclusive of issue costs (4,526 ) — Debt $ 15,474 $ 9,716 The following table sets forth the contractual future principal payments as of September 30, 2015 : Years Ending December 31 2015 (October 1 to December 31) $ — 2016 — 2017 1,000 2018 3,500 2019 6,000 Thereafter 9,500

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share Basic and diluted net loss, per common share have been calculated in accordance with ASC Topic 260, “Earnings Per Share” , for the three and nine month periods ended September 30, 2015 and 2014 . As the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same. The computation of basic net loss per common share for the three and nine month periods ended September 30, 2015 and 2014 excluded 0 and 29,600 shares of restricted stock, respectively (see Note 5). While these restricted shares of stock are included in outstanding shares on the condensed balance sheet, these restricted shares are excluded from basic net loss per common share in accordance with ASC Topic 260 due to the forfeiture provisions associated with these shares. The computations of diluted net loss per common share for the three and nine month periods ended September 30, 2015 and 2014 did not include the outstanding shares of restricted stock, options to acquire common stock, common stock warrants, and convertible preferred stock, as the inclusion of these securities would have been antidilutive: Nine Months Ended September 30, 2015 2014 Restricted stock — 29,600 Stock options 631,080 268,122 Common stock warrants 3,521,610 6,801 4,152,690 304,523

Equity Incentive Plan

Equity Incentive Plan	9 Months Ended
	Sep. 30, 2015
Equity Incentive Plan	Equity Incentive Plan The Company’s board of directors has adopted and the shareholders have approved the Nanosphere, Inc. 2000 Equity Incentive Plan (the “2000 Plan”), the Nanosphere, Inc. 2007 Long-Term Incentive Plan (the “2007 Plan”) and the Nanosphere, Inc. 2014 Long-Term Incentive Plan (the “2014 Plan,” and together with the 2000 Plan and the 2007 Plan, the “Plans”). Upon adoption of the 2014 Plan at the Company’s annual meeting of shareholders on May 28, 2014, the 2000 Plan and 2007 Plan were terminated. The Plans authorize the compensation committee to grant stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, incentive stock options, deferred share units and performance awards. Option awards are generally granted with an exercise price equal to or above the fair value of the Company’s common stock at the date of grant with ten year contractual terms. Certain options vest ratably, generally over three to four years of service, while other options cliff vest after seven years of service but provide for accelerated vesting contingent upon the achievement of various company-wide performance goals, such as decreasing time to market for new products and entering into corporate collaborations (as defined in the option grant agreements). For these “accelerated vesting” options, 20% - 25% of the granted option shares will vest upon the achievement of each of four or five milestones as defined in the option grant agreements, with any remaining unvested options vesting on the seven year anniversary of the option grant dates. Approximately 11% of the options granted and outstanding contain “accelerated vesting” provisions. The fair values of the Company’s option awards granted during the nine months ended September 30, 2015 , were estimated at the dates of grant using the Black-Scholes option pricing model with the following assumptions: Expected dividend yield 0.00 % Expected volatility 77% - 78% Risk free interest rate 1.49% - 1.92% Weighted-average expected option life in years 5.5 - 6.0 Estimated weighted-average fair value on the date of grant based on the above assumptions $1.09 - $3.38 Estimated forfeiture rate for unvested options 10% - 18.03% The expected volatility for option awards granted in 2015 was based on the Company’s actual historical volatility. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of the grants for periods consistent with the expected life of the option. The expected life of options that vest ratably over four years of service is derived from the average of the vesting period and the term of the option as defined in the Plans, following the guidance in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin Nos. 107 and 110. The Company estimates the expected life of options with accelerated vesting terms giving consideration to the dates that the Company expects to achieve key milestones under the option agreements and the term of the option. Total compensation cost recognized for all stock option awards was $0.2 million and $0.7 million in the three and nine month periods ended September 30, 2015 , respectively, and $0.8 million and $2.6 million for the same periods ended September 30, 2014 , respectively. As of September 30, 2015 , the total compensation cost not yet recognized related to the non-vested stock option awards is approximately $1.4 million, which is expected to be recognized over the next three years, with a weighted average term of 1.9 years. Certain milestone events are deemed probable of achievement prior to their seven year vesting term, and the acceleration of vesting resulting from the achievement of such milestone events has been factored into the weighted average vesting term. While the Company does not have a formally established policy, as a practice, the Company has delivered newly issued shares of its common stock upon the exercise of stock options. A summary of option activity under the plans as of September 30, 2015 , for the nine month period ended is presented below: Options Number of Weighted Weighted Aggregate Outstanding - January 1, 2015 266,356 $ 73.20 Granted 436,923 $ 1.69 Exercised — $ — Expired (63,523 ) $ 67.24 Forfeited (8,676 ) $ 9.76 Outstanding - September 30, 2015 631,080 $ 16.58 8.66 $ — Exercisable - September 30, 2015 160,009 $ 66.19 5.45 $ — Vested and Expected to Vest - September 30, 2015 542,572 $ 19.00 5.50 $ — No options were exercised in the nine month period ended September 30, 2015 , and 467,500 options were exercised in the same period ended in 2014. Included in the number of options outstanding at September 30, 2015 are 20,077 options with a weighted average exercise price of $106.98 per share, which have accelerated vesting provisions based on the criteria mentioned above. The total fair value of shares vested during the three and nine months ended September 30, 2015 was $0.1 million and $1.0 million, respectively, and $0.1 million and $1.9 million, for the same periods in 2014. A summary of the restricted shares activity under the plans as of September 30, 2015 , for the nine month period ended is presented below: Restricted Stock Number of Outstanding - January 1, 2015 29,175 Granted — Vested (24,050 ) Forfeited (5,125 ) Outstanding - September 30, 2015 — During the three months ended September 30, 2015, the Company recognized no restricted stock compensation expense due to forfeitures, and less than $0.1 million of restricted stock compensation expense during the nine months ended September 30, 2015. Restricted stock compensation expenses for the three and nine months ended September 30, 2014 were $0.5 million and $1.7 million respectively. As of September 30, 2015 , there are no outstanding restricted stock.

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Preferred Stock	Preferred Stock Series A Convertible Preferred Stock The Company issued and sold 4,400 shares of Series A Preferred Stock to the Investors on May 14, 2015. The Series A Preferred Stock, par value $0.01 , was sold for $1,000 per share and was convertible at any time at the holder’s option, and did actually convert in a series of conversions in May and June 2015, at a conversion rate of $3.765 per share into 1,168,659 shares of the Company's common stock. I n a concurrent private placement, the Company issued the Series A Warrants to the Investors and the placement agent for the Series A Offering, which are exercisable into up to 1,238,779 shares of our common stock with the 1,168,659 Series A Investor Warrants having an exercise price of $3.65 per share and the Series A Placement Agent Warrants having an exercise price of $4.45 per share, in each case subject to certain customary anti-dilution adjustments. The Series A Investor Warrants are exercisable at any time between November 14, 2015 and November 14, 2020. The Series A Placement Agent Warrants are exercisable at any time between November 14, 2015 and May 14, 2020. The Series A Warrants can be settled in shares of our common stock by cashless exercise in lieu of payment of the exercise price at the option of the investors if the underlying shares are not then registered for resale. The Series A Warrant holders will participate in any dividends declared and paid to common stock holders on an ‘as-exercised’ basis, and will be held in abeyance until the warrants are exercised. The Company has determined that the Series A Warrants qualify for accounting as equity instruments rather than as liabilities. As of the May 14, 2015 issuance date, the Company estimated the fair value of the Series A Investor Warrants at $3.2 million under the Black-Scholes option pricing model using the following primary assumptions: contractual term of 5.5 years, volatility rate of 77.26% , risk-free interest rate of 1.62% and expected dividend rate of 0% . Based on the Series A Investor Warrant’s relative fair value to the fair value of the Series A Preferred Stock, $1.6 million of the $4.4 million of proceeds was allocated to the Series A Investor Warrants, creating a corresponding preferred stock discount in the same amount. The Company assessed the Series A Preferred Stock and the related Series A Warrants under ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”), ASC Topic 815, “Derivatives and Hedging” (“ASC 815”), and ASC Topic 470, “Debt” (“ASC 470”). The preferred stock contains an embedded feature allowing an optional conversion by the holder into common stock which meets the definition of a derivative. However, we determined that the preferred stock is an “equity host” (as described by ASC 815) for purposes of assessing the embedded derivative for potential bifurcation and that the optional conversion feature is clearly and closely associated to the preferred stock host; therefore the embedded derivative does not require bifurcation and separate recognition under ASC 815. We determined there to be a beneficial conversion feature (“BCF”) requiring recognition at its intrinsic value. Since the conversion option of the preferred stock was immediately exercisable, the amount allocated to the BCF was immediately accreted to preferred dividends, resulting in an increase in the carrying value of the preferred stock. We also assessed the Series A Warrants under ASC 815 and determined that they did not initially meet the definition of a derivative, but will require evaluation on an on-going basis. As of September 30, 2015, we determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition. On May 14, 2015 the Company recorded a deemed dividend of $2.2 million related to the beneficial conversion feature with the issuance of the Series A Convertible Preferred stock. As of June 30, 2015, all Series A Preferred Stock had converted to common stock. Upon conversion the Company recorded an additional deemed dividend of $1.6 million. Series B Convertible Preferred Stock The Company issued and sold 4,400 shares of Series B Preferred Stock on June 11, 2015. The Series B Preferred Stock, par value $0.01 , was sold for $1,000 per share and is convertible at any time at the holder’s option and did actually convert in a series of conversions in June and September 2015, at a conversion rate of $3.655 per share (subject to certain, customary anti-dilution provisions) into 1,203,800 shares of the Company's common stock. In a concurrent private placement, the Company issued the Series B Warrants to the Investors and the placement agent for the Series B Offering for no additional consideration. The Series B Warrants are exercisable into up to 1,276,060 shares of our common stock at an exercise price of $3.54 per share (subject to certain, customary anti-dilution provisions). The Series B Investor Warrants are exercisable at any time between December 11, 2015 and December 11, 2020. The Series B Placement Agent Warrants are exercisable at any time between December 11, 2015 and June 08, 2020. The terms of the Series B Warrants and related registration rights agreement are otherwise identical to those of the Series A Warrants. As of the June 11, 2015 issuance date, the Company estimated the fair value of the Series B Investor Warrants at $2.9 million under the Black-Scholes option pricing model using the following primary assumptions: contractual term of 5.5 years, volatility rate of 77.36% , risk-free interest rate of 1.82% and expected dividend rate of 0% . Based on the Series B Investor Warrant’s relative fair value to the fair value of the Series B Stock, $1.6 million of the $4.4 million of proceeds was allocated to the Series B Investor Warrants, creating a corresponding preferred stock discount in the same amount. We assessed the Series B Preferred Stock and Series B Warrants using the same methodology as for the Series A Preferred Stock and Series A Warrants(see discussion above), and resulting in the same determinations. On June 8, 2015 the Company recorded a deemed dividend of $1.5 million related to the beneficial conversion feature with the issuance of the Series B Convertible Preferred stock. For the three and nine month periods ended September 30, 2015, 3,107 and 4,400 of Series B Preferred Stock, respectively, had converted to common stock. Upon conversion, for the three and nine month periods ended September 30, 2015, the Company recorded an additional deemed dividend of $1.1 million and $1.6 million, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets, consisting of purchased intellectual property, as of September 30, 2015 and December 31, 2014 comprise the following (in thousands): September 30, 2015 December 31, 2014 Cost Additions Accumulated Net Cost Accumulated Net Intellectual property - licenses $ 3,263 $ 68 $ (1,640 ) $ 1,691 $ 3,263 $ (1,432 ) $ 1,831 Patents 455 (241 ) 214 455 (206 ) 249 Total $ 3,718 $ 68 $ (1,881 ) $ 1,905 $ 3,718 $ (1,638 ) $ 2,080 Licenses are amortized from the date of initial use of the licensed technology and such amortization continues over the remaining life of the license. The future amortization expense reflected in the table below is based on licenses for which the licensed technology is being used as of September 30, 2015 . The Company reviews its long-lived assets for impairment as a single asset group whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company will continue to monitor the recoverability of its long-lived assets. If results continue to decline, it could result in revisions to management’s estimates of the fair value of the asset group and may result in future charges. Amortization expense for intangible assets was $0.1 million, and $0.2 million for the three and nine month periods ended September 30, 2015 , and 2014 respectively. Estimated future amortization expense is as follows (in thousands): Years Ending December 31 2015 (October 1 to December 31) $ 81 2016 317 2017 301 2018 219 2019 211 Thereafter 776

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
License Agreements	License Agreements The Company has entered into several nonexclusive license agreements with various companies covering certain technologies which are embedded in the Company’s diagnostic instruments and diagnostic test products. As of September 30, 2015 , the Company has paid aggregate initial license fees of $3.8 million for these licenses, and has agreed to pay a percentage of net sales as royalties, in percentage amounts ranging from less than 1.0% to 12.0% . These initial license fees were capitalized as intangible assets (see Note 7). Certain license agreements have minimum annual royalty payments, and such minimum payments are $0.2 million in 2015, and are less than $0.1 million annually thereafter through the dates the respective licenses terminate. These licenses expire at various times, corresponding to the subject patents expirations, which currently range from 2015 to 2027 .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies In November 2013, the Company exercised its renewal option on the lease at its corporate headquarters, and the lease term was extended to May 2017. Rent and operating expenses associated with the office and laboratory space were $0.2 million and $0.5 million for the three and nine months periods ended September 30, 2015 , and 2014 , respectively. On January 1, 2015 the Company was leasing 40,749 square feet of space for its administrative, executive, research and development, and manufacturing functions. On February 16, 2015, the Company exercised an option under its lease to acquire an additional 7,721 square feet of space at its corporate headquarters to expand its manufacturing facility, now leasing a total of 48,470 square feet. With this additional space, the annual future minimum obligations, including common area maintenance (CAM), for the operating leases as of September 30, 2015 , are as follows (in thousands): Years Ending December 31 Operating 2015 (October to December 31) $ 125 2016 793 2017 350 Total minimum lease payments $ 1,268

Restructuring Costs

Restructuring Costs	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Costs	Restructuring Costs In January 2015, the Company eliminated certain full time positions, and recorded a restructuring expense of $0.5 million for severance. The Company has paid the severance through September 2015. The table below shows the beginning provision, and payments made during each of the three months periods ended: Three months ended March 31, 2015 Three months ended June 30, 2015 Three months ended September 30, 2015 Cost Payments Balance Payments Balance Payments Balance Provision for Restructure (in thousands) $ 513 $ (266 ) $ 247 $ (198 ) $ 49 $ (49 ) $ —

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Financial Information	Supplemental Financial Information Inventories (in thousands): September 30, 2015 December 31, 2014 Raw materials $ 3,386 $ 3,041 Work-in-process 130 162 Finished goods 3,259 6,184 Inventories $ 6,775 $ 9,387 Accounts Receivable (in thousands): September 30, 2015 December 31, 2014 Accounts receivable $ 3,502 $ 4,379 Allowance for doubtful accounts (188 ) (87 ) Accounts receivable - net $ 3,314 $ 4,292 Property and Equipment (in thousands): September 30, 2015 December 31, 2014 Property and equipment - at cost $ 22,008 $ 22,435 Less accumulated depreciation (16,579 ) (18,624 ) Construction-in-Progress 2,984 1,261 Property and equipment - net $ 8,413 $ 5,072 Other Current Liabilities (in thousands): September 30, 2015 December 31, 2014 Accrued clinical trial expenses $ 780 $ 1,858 Accrued license fees 41 65 All other 2,413 1,250 Other current liabilities $ 3,234 $ 3,173 Three months ended September 30, Nine months ended September 30, Product Reporting: 2015 2014 2015 2014 Revenues: Instruments $ 815 $ 1,278 $ 2,433 $ 2,291 Consumables 4,073 2,410 11,791 7,352 Total revenues $ 4,888 $ 3,688 $ 14,224 $ 9,643

Description of Business and Sig

Description of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation - The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and in conformity with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, in the opinion of management, all adjustments, consisting only of normal recurring adjustments, unless otherwise noted herein, necessary to present fairly the results of operations, financial position and cash flows have been made. Therefore, these condensed financial statements should be read in conjunction with the Company’s most recent audited financial statements for the year ended December 31, 2014 and notes thereto included in the Company’s Annual Report on Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations expected for the full year.
Deferred Financing Costs	Deferred Financing Costs - Costs incurred to issue debt are deferred and amortized as a component of interest expense using the effective interest method over the term of the related debt agreement.
Use of Estimates	Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the condensed financial statements are related to inventories, property and equipment, intangible assets, debt, preferred stock, warrants, and share-based compensation. Actual results could differ from those estim
Fair Value of Financial Instruments	tes. Fair Value of Financial Instruments - The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable approximate their fair va
New Accounting Pronouncements	erations. Impairment of Intangible Assets - The Company monitors the carrying value of long-lived assets for potential impairment and tests the recoverability of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. Evaluation Equipment - The Company monitors inventory held at customer sites for evaluation (“Evaluation Equipment”). Upon determination that such Evaluation Equipment is no longer available for sale and is to remain with the customer, Evaluation Equipment is reclassified to property plant and equipment as leased equipment, which is typically after twelve months following initial placement. During the three and nine month periods ended September 30, 2015, the Company reclassified $2.9 million of Evaluation Equipment to property, plant, and equipment. The Company commences depreciation on the date of transfer and such Evaluation Equipment is depreciated over a three year period. New Accounting Pronouncements - In May 2014, the FASB issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers , (“ASU No. 2014-09”) an updated standard on revenue recognition. ASU No. 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU No. 2014-09, which will be effective for the Company in the first quarter of 2018 and may be applied on a full retrospective or modified retrospective approach. The Company is evaluating the impact of implementation and transition approach of this standard on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known (and reasonably knowable) at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company currently discloses its uncertainty about its ability to continue as a going concern. The Company does not expect the adoption of ASU No. 2014-15 to have a material impact on its disclosures or its consolidated financial statement. In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. ASU No. 2015-03 is effective for the interim and annual periods ending after December 15, 2015, with early adoption permitted. As of June 30, 2015, the Company adopted ASU No. 2015-03 and such adoption resulted in debt issuance costs for all periods presented to be reclassified to debt. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventories by replacing the lower of cost or market test with a lower of cost and net realizable value test. The guidance applies only to inventories for which cost is determined by methods other than last-in first-out ("LIFO") and the retail inventory method. The guidance in ASU No. 2015-11 is effective for periods beginning after December 15, 2016 and early adoption is permitted. The Company will adopt this pronouncement in the first quarter of 2017 and is currently evaluating the impact, if any, adoption will have on its financial position and results of operations. Reclassifications - Certain information as of December 31, 2014 presented in the financial statements have been reclassified to the current presentation. These reclassifications include: i) the reclassification of $0.1 million of debt issuance costs upon the early adoption of ASU No. 2015-03 to debt on the condensed balance sheets, ii) the combination of warrants to acquire common stock within additional paid in capital on the condensed balance sheets and condensed statement of stockholders’ equity, and iii) the separate presentation of depreciation and amortization and accounts receivable and provision for doubtful accounts on the condensed statements of cash flows, iv) the combination of foreign exchange gain/ loss and interest income on the income statement. These reclassifications had no impact on the results of operations, financial position, or cash flows. Restricted Cash - Any cash that is legally restricted from use is recorded in restricted cash on the condensed balance sheets. The new term loan facility (See Note 2) requires the Company to maintain a minimum account balance which is considered to be restricted cash. The restricted cash balance was $4 million on September 30, 2015 and there was no restricted cash on December 31, 2014. Comprehensive Loss - The Company’s comprehensive loss is equal to its net loss for all periods

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following table summarizes the Company's debt as of September 30, 2015 and December 31, 2014 : September 30, 2015 December 31, 2014 Silicon Valley Bank and Oxford Finance LLC $ — $ 9,919 Debt discount, inclusive of issue costs — (203 ) — 9,716 NSPH Funding LLC and SWK Funding LLC 20,000 — Debt discount, inclusive of issue costs (4,526 ) — Debt $ 15,474 $ 9,716
Schedule of Maturities of Long-term Debt	The following table sets forth the contractual future principal payments as of September 30, 2015 : Years Ending December 31 2015 (October 1 to December 31) $ — 2016 — 2017 1,000 2018 3,500 2019 6,000 Thereafter 9,500

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Antidilutive Common Stock and Common Stock Warrants	The computations of diluted net loss per common share for the three and nine month periods ended September 30, 2015 and 2014 did not include the outstanding shares of restricted stock, options to acquire common stock, common stock warrants, and convertible preferred stock, as the inclusion of these securities would have been antidilutive: Nine Months Ended September 30, 2015 2014 Restricted stock — 29,600 Stock options 631,080 268,122 Common stock warrants 3,521,610 6,801 4,152,690 304,523

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2015
Assumptions Used Fair Value of Option Awards Granted Using Black-Scholes Option Pricing Model	The fair values of the Company’s option awards granted during the nine months ended September 30, 2015 , were estimated at the dates of grant using the Black-Scholes option pricing model with the following assumptions: Expected dividend yield 0.00 % Expected volatility 77% - 78% Risk free interest rate 1.49% - 1.92% Weighted-average expected option life in years 5.5 - 6.0 Estimated weighted-average fair value on the date of grant based on the above assumptions $1.09 - $3.38 Estimated forfeiture rate for unvested options 10% - 18.03%
Summary of Option Activity	e of stock options. A summary of option activity under the plans as of September 30, 2015 , for the nine month period ende

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Consisting of Purchased Intellectual Property	Intangible assets, consisting of purchased intellectual property, as of September 30, 2015 and December 31, 2014 comprise the following (in thousands): September 30, 2015 December 31, 2014 Cost Additions Accumulated Net Cost Accumulated Net Intellectual property - licenses $ 3,263 $ 68 $ (1,640 ) $ 1,691 $ 3,263 $ (1,432 ) $ 1,831 Patents 455 (241 ) 214 455 (206 ) 249 Total $ 3,718 $ 68 $ (1,881 ) $ 1,905 $ 3,718 $ (1,638 ) $ 2,080
Schedule of Estimated Future Amortization Expense	Estimated future amortization expense is as follows (in

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Annual Future Minimum Obligations for Operating Leases	With this additional space, the annual future minimum obligations, including common area maintenance (CAM), for the operating leases as of September 30, 2015 , are as follows (in thousands): Years Ending December 31 Operating 2015 (October to December 31) $ 125 2016 793 2017 350 Total minimum lease payments $ 1,268

Restructuring Costs (Tables)

Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Costs	The table below shows the beginning provision, and payments made during each of the three months periods ended: Three months ended March 31, 2015 Three months ended June 30, 2015 Three months ended September 30, 2015 Cost Payments Balance Payments Balance Payments Balance Provision for Restructure (in thousands) $ 513 $ (266 ) $ 247 $ (198 ) $ 49 $ (49 ) $ —

Supplemental Financial Inform25

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2015
Supplemental Cash Flow Elements [Abstract]
Inventories	Inventories (in thousands): September 30, 2015 December 31, 2014 Raw materials $ 3,386 $ 3,041 Work-in-process 130 162 Finished goods 3,259 6,184 Inventories $ 6,775 $ 9,387
Accounts Receivable Net	Accounts Receivable (in thousands): September 30, 2015 December 31, 2014 Accounts receivable $ 3,502 $ 4,379 Allowance for doubtful accounts (188 ) (87 ) Accounts receivable - net $ 3,314 $ 4,292
Property and Equipment-Net	Property and Equipment (in thousands): September 30, 2015 December 31, 2014 Property and equipment - at cost $ 22,008 $ 22,435 Less accumulated depreciation (16,579 ) (18,624 ) Construction-in-Progress 2,984 1,261 Property and equipment - net $ 8,413 $ 5,072
Other Current Liabilities	Other Current Liabilities (in thousands): September 30, 2015 December 31, 2014 Accrued clinical trial expenses $ 780 $ 1,858 Accrued license fees 41 65 All other 2,413 1,250 Other current liabilities $ 3,234 $ 3,173
Revenues	Three months ended September 30, Nine months ended September 30, Product Reporting: 2015 2014 2015 2014 Revenues: Instruments $ 815 $ 1,278 $ 2,433 $ 2,291 Consumables 4,073 2,410 11,791 7,352 Total revenues $ 4,888 $ 3,688 $ 14,224 $ 9,643

Description of Business and S26

Description of Business and Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Thousands	Apr. 08, 2015	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt Instrument, Fair Value Disclosure		$ 15,600		$ 15,600		$ 9,800
Stockholders' Equity, Reverse Stock Split	20
common stock, shares authorized (shares) | shares		150,000,000		150,000,000		150,000,000
common stock, par value (usd per share) | $ / shares		$ 0.01		$ 0.01		$ 0.01
Debt instrument, effective interest rate (percentage)		20.90%		20.90%
Debt - net		$ 15,474		$ 15,474		$ 9,716
Restricted cash		4,000		4,000		0
Maximum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Amortization of deferred financing costs		200	$ 100	$ 300	$ 100
New Accounting Pronouncement, Early Adoption, Effect
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt - net						$ 100
Equipment Leased to Other Party
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Useful life (years)				3 years
Assets Held-for-sale
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Reclassification adjustment		$ 2,900		$ 2,900

Liquidity, Capital Resources an

Liquidity, Capital Resources and Recent Developments - Additional Information (Detail)	Jul. 29, 2015USD ($)	Jun. 11, 2015USD ($)	Jun. 08, 2015USD ($)$ / sharesshares	May. 14, 2015USD ($)fiscal_quartershares	May. 13, 2015$ / sharesshares	May. 11, 2015USD ($)$ / sharesshares	Dec. 31, 2015	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2014USD ($)$ / shares
Liquidity and Capital Resources [Line Items]
Accumulated deficit								$ (446,831,000)	$ (446,831,000)	$ (446,831,000)	$ (446,831,000)			$ (421,906,000)
Total cash and cash equivalents, including restricted cash								16,300,000	16,300,000	16,300,000	16,300,000
Restricted cash								$ 4,000,000	$ 4,000,000	$ 4,000,000	4,000,000			$ 0
Net cash used in operating activities											(20,630,000)	$ (26,291,000)
Issuance of convertible preferred stock											$ 8,800,000
common stock, par value (usd per share) | $ / shares								$ 0.01	$ 0.01	$ 0.01	$ 0.01			$ 0.01
Exercise price of warrants (usd per share) | $ / shares						$ 3.65
Proceeds from issuance of equity		$ 4,400,000				$ 4,000,000					$ 4,400,000
Preferred stock, par value (usd per share) | $ / shares								$ 0.01	$ 0.01	$ 0.01	$ 0.01			$ 0.01
Silicon Valley Bank and Oxford Finance LLC
Liquidity and Capital Resources [Line Items]
Repayments of line of credit				$ 8,900,000
Convertible Preferred Stock
Liquidity and Capital Resources [Line Items]
Issuance of convertible preferred stock						$ 4,400,000
Share Price (usd per share) | $ / shares						$ 3.765
Liquidation preference per share | $ / shares						$ 0.01
Conversion of stock (shares) | shares										4,400
Common Stock
Liquidity and Capital Resources [Line Items]
Number of shares convertible into (shares) | shares			1,203,800
Conversion of stock, shares issued | shares						1,168,659			1,203,800	1,168,659
Number of common stock called by warrants | shares				1,238,779	1,168,659	70,120
Exercise price of warrants (usd per share) | $ / shares						$ 4.45
Series B Preferred Stock
Liquidity and Capital Resources [Line Items]
Issuance of convertible preferred stock			$ 4,400,000
Number of shares convertible into (shares) | shares			1,203,800
Share Price (usd per share) | $ / shares			$ 3.655
Number of common stock called by warrants | shares			72,230
Exercise price of warrants (usd per share) | $ / shares			$ 3.54
Preferred stock, par value (usd per share) | $ / shares			$ 0.01
Conversion of stock (shares) | shares								3,107	4,400		4,400
Series A Warrants
Liquidity and Capital Resources [Line Items]
Warrants and Rights Outstanding				$ 3,200,000
Proceeds from issuance of equity											$ 1,600,000
Series B Warrants
Liquidity and Capital Resources [Line Items]
Warrants and Rights Outstanding		2,900,000	$ 1,600,000
Exercise price of warrants (usd per share) | $ / shares			$ 3.54
Proceeds from issuance of equity		1,600,000
Series B Warrants | Common Stock
Liquidity and Capital Resources [Line Items]
Number of common stock called by warrants | shares			1,276,060
Series B Warrants | Series B Preferred Stock
Liquidity and Capital Resources [Line Items]
Number of common stock called by warrants | shares			1,203,800
Minimum | Common Stock
Liquidity and Capital Resources [Line Items]
Expiration period						4 years 6 months
Minimum | Series B Preferred Stock
Liquidity and Capital Resources [Line Items]
Expiration period			4 years 6 months
Maximum | Common Stock
Liquidity and Capital Resources [Line Items]
Expiration period						5 years
Maximum | Series B Preferred Stock
Liquidity and Capital Resources [Line Items]
Expiration period			5 years
2015 Loan Agreement | Common Stock
Liquidity and Capital Resources [Line Items]
Number of common stock called by warrants | shares					1,000,000
Expiration period					10 years
Warrants and Rights Outstanding				$ 3,900,000
Exercise price of warrants (usd per share) | $ / shares					$ 0.01
Series B Purchase Agreement
Liquidity and Capital Resources [Line Items]
Proceeds from issuance of equity		$ 4,000,000
Line of Credit | 2015 Loan Agreement
Liquidity and Capital Resources [Line Items]
Amortization ratio								3.5
Number of successive quarters to accelerate payment | fiscal_quarter				2
Minimum quarterly amortization				$ 3,300,000
Number of fiscal quarters to payoff outstanding term loan facility | fiscal_quarter				6
Line of Credit | 2015 Loan Agreement | Scenario, Forecast
Liquidity and Capital Resources [Line Items]
Amortization ratio							2.6
Loans Payable | 2015 Loan Agreement
Liquidity and Capital Resources [Line Items]
Debt face amount				$ 30,000,000
Proceeds from debt				20,000,000
Minimum balance of accounts subject to control agreement	$ 4,000,000			$ 3,000,000
Debt term				6 years
Stated interest rate				11.50%
Minimum spread over stated rate				1.00%
Maximum stated rate				5.00%
Debt fee amount				$ 450,000
Repayment fee, percent of aggregate principal amount funded				5.00%
Repayment fee as percent of principal amount prepaid in year one				2.00%
Repayment fee as percent of principal amount prepaid in year two and three				1.00%
Minimum net financing proceeds	$ 4,000,000			$ 6,000,000
Minimum net proceeds to be received				6,000,000
Loans Payable | 2015 Loan Agreement | Scenario, Forecast
Liquidity and Capital Resources [Line Items]
Minimum balance of accounts subject to control agreement													$ 5,000,000
Loans Payable | Second Advance
Liquidity and Capital Resources [Line Items]
Debt face amount				10,000,000
Minimum revenues				$ 12,000,000
Minimum revenues, required period				6 months
Maximum number of cumulative units can be sold | shares				100

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term Debt	$ 15,474	$ 9,716
Loans Payable | Silicon Valley Bank and Oxford Finance LLC
Debt Instrument [Line Items]
Long-term Debt, Gross	0	9,919
Debt discount, inclusive of issue costs	0	(203)
Long-term Debt	0	9,716
Line of Credit | NSPH Funding, LLC and SWK Funding, LLC
Debt Instrument [Line Items]
Long-term Debt, Gross	20,000	0
Debt discount, inclusive of issue costs	$ (4,526)	$ 0

Debt - Repayments of Principal

Debt - Repayments of Principal and Interest (Details) $ in Thousands	Sep. 30, 2015USD ($)
Debt Disclosure [Abstract]
2015 (October 1 to December 31)	$ 0
2,016	0
2,017	1,000
2,018	3,500
2,019	6,000
Thereafter	$ 9,500

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of basic net loss per common share			4,152,690	304,523
Restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation of basic net loss per common share	0	29,600	0	29,600

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive common stock and common stock warrants			4,152,690	304,523
Restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive common stock and common stock warrants	0	29,600	0	29,600
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive common stock and common stock warrants			631,080	268,122
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive common stock and common stock warrants			3,521,610	6,801

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Cliff Vesting Period			7 years
Percentage of options granted and outstanding with accelerated vesting provisions			11.00%
Total compensation cost associated with option awards	$ 0.2	$ 0.8	$ 0.7	$ 2.6
Total compensation cost not yet recognized	$ 1.4		$ 1.4
Unrecognized share based compensation recognition period			3 years
Milestone vesting term			7 years
Weighted average term remains			1 year 11 months 5 days
Options exercised			0	467,500
Number of Options Outstanding with accelerated vesting provisions	20,077		20,077
Weighted average exercise options with accelerated vesting provisions	$ 106.98		$ 106.98
Total fair value of shares, vested	$ 0.1	0.1	$ 1	$ 1.9
Restricted stock compensation expense (credit)	$ 0	$ 0.5	$ 0.1	$ 1.7
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock, outstanding	0		0		29,175
Restricted stock, forfeited			5,125
Granted			0
Restricted stock, vested			24,050
Equity Incentive Plan 2000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards contractual terms			10 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards, vesting period			3 years
Accelerated vesting options			20.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards, vesting period			4 years
Accelerated vesting options			25.00%

Equity Incentive Plan - Assumpt

Equity Incentive Plan - Assumptions Used for Fair Value of Option Awards Granted Using Black-Scholes Option Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2015$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	77.00%
Risk free interest rate	1.49%
Weighted-average expected option life in years	5 years 6 months
Estimated weighted-average fair value on the date of grant based on the above assumptions	$ 1.09
Estimated forfeiture rate for unvested options	10.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	78.00%
Risk free interest rate	1.92%
Weighted-average expected option life in years	6 years
Estimated weighted-average fair value on the date of grant based on the above assumptions	$ 3.38
Estimated forfeiture rate for unvested options	18.03%

Equity Incentive Plan - Summary

Equity Incentive Plan - Summary of Option Activity (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Number of Shares
Outstanding - January 1, 2015	266,356.4
Granted	436,923
Exercised	0	467,500
Expired	(63,523)
Forfeited	(8,676)
Outstanding - March 31, 2015	631,080
Exercisable - March 31, 2015	160,009
Vested and Expected to Vest- March 31, 2015	542,572
Weighted Average Exercise Price
Outstanding - January 1, 2015	$ 73.20
Granted	1.69
Exercised	0
Expired	67.24
Forfeited	9.76
Outstanding - March 31, 2015	16.58
Exercisable - March 31, 2015	66.19
Vested and Expected to Vest-March 31, 2015	$ 19
Weighted Average Remaining Contractual Term
Outstanding - March 31, 2015	8 years 7 months 28 days
Exercisable - March 31, 2015	5 years 5 months 12 days
Vested and Expected to Vest-March 31, 2015	5 years 6 months
Aggregate Intrinsic Value of Options
Outstanding - March 31, 2015	$ 0
Exercisable - March 31, 2015	0
Vested and Expected to Vest-March 31, 2015	$ 0

Equity Incentive Plan - Summa35

Equity Incentive Plan - Summary of Restricted Shares Activity (Details) - Restricted stock	9 Months Ended
	Sep. 30, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding - January 1, 2015	29,175
Granted	0
Stock Issued During Period Shares Restricted Stock Award Vested	(24,050)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited	(5,125)
Outstanding - September 30, 2015	0

Preferred Stock - Narrative (De

Preferred Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 30, 2015	Jun. 11, 2015	Jun. 08, 2015	May. 14, 2015	May. 11, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	May. 13, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred stock, par value (usd per share)						$ 0.01	$ 0.01	$ 0.01		$ 0.01		$ 0.01
Exercise price of warrants (usd per share)					$ 3.65
Proceeds from issuance of equity		$ 4.4			$ 4					$ 4.4
Series A Warrants
Class of Stock [Line Items]
Warrants outstanding (shares)				1,168,659
Warrants and Rights Outstanding				$ 3.2
Fair Value Assumptions, Expected Term				5 years 6 months
Fair Value Assumptions, Expected Volatility Rate				77.26%
Fair Value Assumptions, Risk Free Interest Rate				1.62%
Fair Value Assumptions, Expected Dividend Rate				0.00%
Proceeds from issuance of equity										$ 1.6
Series B Warrants
Class of Stock [Line Items]
Exercise price of warrants (usd per share)			$ 3.54
Warrants and Rights Outstanding		$ 2.9	$ 1.6
Fair Value Assumptions, Expected Term			5 years 6 months
Fair Value Assumptions, Expected Volatility Rate		77.36%
Fair Value Assumptions, Risk Free Interest Rate		1.82%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Proceeds from issuance of equity		$ 1.6
Series A
Class of Stock [Line Items]
Issuance of convertible preferred stock, stock				4,400
Preferred stock, par value (usd per share)				$ 0.01
Price per share (usd per share)				$ 1,000
Share Price (usd per share)						$ 3.765	$ 3.765	$ 3.765		$ 3.765
Deemed dividend on conversion of preferred stock to common stock	$ 1.6			$ 2.2
Common Stock
Class of Stock [Line Items]
Number of shares convertible into (shares)			1,203,800
Conversion of stock, shares issued					1,168,659		1,203,800	1,168,659
Number of common stock called by warrants				1,238,779	70,120						1,168,659
Exercise price of warrants (usd per share)					$ 4.45
Common Stock | Series B Warrants
Class of Stock [Line Items]
Number of common stock called by warrants			1,276,060
Common Stock | Series A
Class of Stock [Line Items]
Conversion of stock, shares issued									1,168,659
Series B Preferred Stock
Class of Stock [Line Items]
Issuance of convertible preferred stock, stock			4,400
Preferred stock, par value (usd per share)			$ 0.01
Price per share (usd per share)			1,000
Share Price (usd per share)			$ 3.655
Number of shares convertible into (shares)			1,203,800
Number of common stock called by warrants			72,230
Exercise price of warrants (usd per share)			$ 3.54
Deemed dividend on conversion of preferred stock to common stock			$ 1.5			$ 1.1				$ 1.6
Conversion of stock (shares)						3,107	4,400			4,400
Series B Preferred Stock | Series B Warrants
Class of Stock [Line Items]
Number of common stock called by warrants			1,203,800
Investor | Series A Warrants
Class of Stock [Line Items]
Exercise price of warrants (usd per share)				$ 3.65
Placement Agent | Series A Warrants
Class of Stock [Line Items]
Exercise price of warrants (usd per share)				$ 4.45

Intangible Assets (Detail)

Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Cost	$ 3,718	$ 3,718
Additions	68
Accumulated Amortization	(1,881)	(1,638)
Net	1,905	2,080
Intellectual property - licenses
Finite-Lived Intangible Assets [Line Items]
Cost	3,263	3,263
Additions	68
Accumulated Amortization	(1,640)	(1,432)
Net	1,691	1,831
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	455	455
Accumulated Amortization	(241)	(206)
Net	$ 214	$ 249

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense for intangible assets	$ 0.1	$ 0.2

Intangible Assets - Estimated F

Intangible Assets - Estimated Future Amortization Expenses (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (Period from April 1 to December 31)	$ 81
2,016	317
2,017	301
2,018	219
2,019	211
Thereafter	$ 776

License Agreements - Additional

License Agreements - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Finite-Lived Intangible Assets [Line Items]
License fees	$ 3.8
Minimum annual royalty payments, 2015	$ 0.2
Minimum
Finite-Lived Intangible Assets [Line Items]
Royalty percentage paid	1.00%
License agreement, expiration date	2,015
Maximum
Finite-Lived Intangible Assets [Line Items]
Royalty percentage paid	12.00%
Minimum annual royalty payments, thereafter	$ 0.1
License agreement, expiration date	2,027

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)ft²	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)ft²	Sep. 30, 2014USD ($)	Feb. 16, 2015ft²	Jan. 01, 2015ft²
Commitments and Contingencies Disclosure [Abstract]
Rent and operating expenses associated with office and laboratory space | $	$ 0.2	$ 0.5	$ 0.4	$ 1.3
Area of leased property	48,470		48,470			40,749
Area of properties leased during the period					7,721

Commitments and Contingencies42

Commitments and Contingencies - Annual Future Minimum Obligations for Operating Leases (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2015 (October to December 31)	$ 125
2,016	793
2,017	350
Total minimum lease payments	$ 1,268

Restructuring Costs (Details)

Restructuring Costs (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Severance Costs	$ 500
Restructuring costs				$ 513
Restructuring Payments		$ (49)	$ (198)	(266)
Provision for Restructure		$ 0	$ 49	$ 247

Supplemental Financial Inform44

Supplemental Financial Information - Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 3,386	$ 3,041
Work-in-process	130	162
Finished goods	3,259	6,184
Inventories	$ 6,775	$ 9,387

Supplemental Financial Inform45

Supplemental Financial Information - Accounts Receivable Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Receivables [Abstract]
Accounts receivable	$ 3,502	$ 4,379
Allowance for doubtful accounts	(188)	(87)
Accounts receivable - net	$ 3,314	$ 4,292

Supplemental Financial Inform46

Supplemental Financial Information - Property and Equipment-Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and equipment - at cost	$ 22,008	$ 22,435
Less accumulated depreciation	(16,579)	(18,624)
Construction-in-Progress	2,984	1,261
Property and equipment - net	$ 8,413	$ 5,072

Supplemental Financial Inform47

Supplemental Financial Information - Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Accrued clinical trial expenses	$ 780	$ 1,858
Accrued license fees	41	65
All other	2,413	1,250
Other current liabilities	$ 3,234	$ 3,173

Supplemental Financial Inform48

Supplemental Financial Information - Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue from External Customer [Line Items]
Total revenue	$ 4,888	$ 3,688	$ 14,224	$ 9,643
Instruments
Revenue from External Customer [Line Items]
Total revenue	815	1,278	2,433	2,291
Consumables
Revenue from External Customer [Line Items]
Total revenue	$ 4,073	$ 2,410	$ 11,791	$ 7,352